Better Yield of 18Fluorodeoxyglucose-Positron Emission Tomography in Patients with Metastatic Differentiated Thyroid Carcinoma during Thyrotropin Stimulation
- 1 May 2002
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Thyroid®
- Vol. 12 (5) , 381-387
- https://doi.org/10.1089/105072502760043459
Abstract
To determine whether (18)fluorodeoxyglucose-positron emission tomography (FDG-PET) for the detection of recurrences or metastases of differentiated thyroid carcinoma should be performed during thyrotropin (TSH) suppression or TSH stimulation, eight patients were studied sequentially. After the second FDG-PET scan, a therapeutic (131)I dose was administered with posttherapy scans obtained 10 days later. Both FDG-PET scans were compared with each other and with the (131)I posttherapy whole body scans by two independent observers. Findings were verified using other imaging modalities or biopsies. Median TSH was 0.04 mU/L during TSH suppression and 64 mU/L during TSH stimulation. The FDG-PET scans during TSH suppression showed abnormalities in four patients and the FDG-PET scan during TSH stimulation in five patients. One patient was only positive during TSH stimulation. In two other patients the FDG-PET scan during TSH stimulation clearly identified more lesions, and in all positive patients lesion contrast was better during TSH stimulation. In two patients FDG-PET findings during TSH stimulation led to a change in clinical management. Thus, the performance of FDG-PET during TSH stimulation was either superior or equal to FDG-PET during TSH suppression, but never inferior. To detect metastatic or recurrent differentiated thyroid carcinoma FDG-PET should be performed during hypothyroidism, leading to TSH stimulation.Keywords
This publication has 17 references indexed in Scilit:
- Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levelsThe American Journal of Surgery, 2000
- Follow-Up in Patients with Differentiated Thyroid Carcinoma with Positive 18F-Fluoro-2-Deoxy- D-Glucose-Positron Emission Tomography Results, Elevated Thyroglobulin Levels, and Negative High-Dose 131I Posttreatment Whole Body ScansJournal of Clinical Endocrinology & Metabolism, 2000
- Prognostic Value of [18F]Fluorodeoxyglucose Positron Emission Tomographic Scanning in Patients with Thyroid CancerJournal of Clinical Endocrinology & Metabolism, 2000
- Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1999
- Imaging of Locally Recurrent and Metastatic Thyroid Cancer with Positron Emission TomographyThyroid®, 1999
- [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Localizes Residual Thyroid Cancer in Patients with Negative Diagnostic 131I Whole Body Scans and Elevated Serum Thyroglobulin LevelsJournal of Clinical Endocrinology & Metabolism, 1999
- Whole-body scintigraphy with 99Tcm-MIBI, 18F-FDG and 131I in patients with metastatic thyroid carcinomaNuclear Medicine Communications, 1997
- Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapyJournal of Clinical Endocrinology & Metabolism, 1993
- The regulation of two distinct glucose transporter (GLUT1 and GLUT4) gene expressions in cultured rat thyroid cells by thyrotropinEndocrinology, 1992